We previously showed that a series of compounds that inhibit the Rho/MRTF pathway, including CCG-257081, could restore BRAFi-sensitivity in human and mouse melanoma cells (Misek et al., 2020; Foda and Neubig, 2023). This evidence concerns the gene RHO and melanoma.